← Back to Search

Unknown

STP1002 for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by ST Pharm Co., Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Study Summary

This trialtests a new drug to find the safest dose for cancer patients.

Eligible Conditions

Advanced Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicities (DLTs)

Secondary outcome measures

The pharmacokinetics of STP1002

Treatment-emergent adverse events (TEAEs)

Trial Design

1Treatment groups

Experimental Treatment

Group I: STP1002Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

STP1002

2020

Completed Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

ST Pharm Co., Ltd.Lead Sponsor

1 Previous Clinical Trials

36 Total Patients Enrolled

KCRN Research, LLCIndustry Sponsor

8 Previous Clinical Trials

417 Total Patients Enrolled

Media Library

STP1002 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04505839 — Phase 1

Solid Tumors Research Study Groups: STP1002

Solid Tumors Clinical Trial 2023: STP1002 Highlights & Side Effects. Trial Name: NCT04505839 — Phase 1

STP1002 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04505839 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still room for potential participants in this research project?

"According to clinicaltrials.gov, this medical trial is open for recruitment and was initially posted on July 30th 2020 with a most recent update occurring almost exactly one year later on September 25th 2021."

Answered by AI

Has the FDA sanctioned STP1002 for therapeutic purposes?

"Due to the preliminary nature of this experiment, our team at Power has conservatively rated STP1002's safety with a score of 1. This is because Phase 1 trials only provide limited insight into efficacy and safety."

Answered by AI

To what extent is the current clinical trial garnering participation?

"Affirmative. According to clinicaltrials.gov, this research endeavour was first posted on July 30th of 2020 and has been actively enrolling participants since then; the last edit took place on September 25th 2021. Altogether, it is hoped that 30 patients will be recruited from 3 distinct medical centres throughout its duration."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

2020. "First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04505839.